Articles related to COMBINATION THERAPY

A recent phase 3 trial has shown that the combination of nivolumab and gemcitabine–cisplatin significantly improves survival rates in patients with previously untreated advanced urothelial carcinoma. This combination therapy resulted in a median survival of 21.7 months compared to 18.9 months with gemcitabine–cisplatin alone.

The EV-302/KEYNOTE-A39 trial has demonstrated a significant improvement in survival outcomes for patients with advanced bladder cancer, with the combination of enfortumab vedotin and pembrolizumab nearly doubling the median progression-free survival and overall survival compared to chemotherapy.

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

The FDA’s recent approval of toripalimab, based on the JUPITER-02 and POLARIS-02 clinical trials, marks a significant milestone in the treatment of nasopharyngeal carcinoma. With a median progression-free survival of 11.7 months, toripalimab has shown promising results in improving patient outcomes.

The recent phase 3 trial has demonstrated the potential of amivantamab as a first-line treatment option for patients with advanced NSCLC with EGFR exon 20 insertions. The combination of amivantamab and chemotherapy significantly improved progression-free survival compared to chemotherapy alone.

The recent phase 1/2 study of Pfizer-BioNTech’s combination vaccine candidate demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. This promising development could significantly impact global immunization practices.